MDASI Chronic Lymphocytic Leukemia Module
The MD Anderson Symptom Inventory for chronic lymphocytic leukemia (MDASI-CLL) is a disease-specific module. Use the MDASI-CLL to assess the severity of symptoms experienced by patients with chronic lymphocytic leukemia and the interference with daily living caused by these symptoms.
The MDASI-CLL is available for licensing, but it has not been psychometrically validated.
Along with the core MDASI’s 13 symptom items and 6 interference items, the MDASI-CLL also assesses 6 symptoms specific to chronic lymphocytic leukemia.
| Core MDASI Symptoms | CLL Symptoms | MDASI Interference |
|---|---|---|
| Pain | Night sweats | Relations with other people |
| Fatigue | Fevers and chills | Enjoyment of life |
| Nausea | Lymph-node swelling | Mood |
| Disturbed sleep | Diarrhea | Walking |
| Distress (feeling upset) | Bruising easily or bleeding | Activity |
| Shortness of breath | Constipation | Work (including housework) |
| Difficulty remembering | ||
| Lack of appetite | ||
| Drowsiness | ||
| Dry mouth | ||
| Sadness | ||
| Vomiting | ||
| Numbness/tingling |
Order the MDASI-CLL
Use our convenient online form to order the MDASI-CLL for use in your clinical research, clinical practice, funded and non-funded academic research, commercial research, or reproduction in educational materials or other publications.
MDASI-CLL Features
- Purpose: To assess the severity of multiple chronic lymphocytic leukemia-related symptoms and the impact of these symptoms on daily functioning
- Population: Patients with symptoms caused by chronic lymphocytic leukemia and its treatment
- Assessment areas: Severity of multiple symptoms and the impact of symptoms on daily functioning during the last 24 hours
- Method: Self-report or interview with research staff; paper-and-pencil or electronic data entry*
- Time required: Five minutes or less
- Scoring: Please see the MDASI User Guide
- Reliability: Cronbach alpha reliability ranges from 0.88 to 0.91
*Electronic data capture offers several benefits:
- Allows symptom monitoring when the patient is away from the hospital
- Is convenient for patients, who can choose web access, personalized patient portals, or smartphones to access questionnaires
- Minimizes missing data, especially in longitudinal studies
- Provides accurate, real-time symptom data at expected time points
- Generates immediate feedback, potentially allowing caregivers to address severe symptoms more effectively
MDASI-CLL Language Versions
Click on a linked language to view a sample in PDF format.
Don't see a language you need? Contact us at symptomresearch@mdanderson.org.
| Psychometrically and Linguistically Validated | Linguistically Validated |
|---|---|
| Arabic | |
| Bulgarian | |
| Chinese (Traditional) | |
| Croatian | |
| Czech | |
| Danish | |
| Dutch | |
| English | |
| Estonian | |
| French | |
| German | |
| Hungarian | |
| Italian | |
| Korean | |
| Latvian | |
| Polish | |
| Portuguese (Brazil) |
|
| Romanian | |
| Russian | |
| Slovak | |
| Spanish | |
| Swedish |
MDASI User Guide
In response to the US Food and Drug Administration's 2009 guidance for the pharmaceutical industry on the use of patient-reported outcomes measures in medical product development to support labeling claims, we have prepared a MDASI User Guide to document the development and psychometric properties of the MDASI and its modules. The User Guide addresses the recommendations in the FDA guidance and establishes the MDASI's adequacy as a measure to support medical product claims.
Selected MDASI-CLL References
Validation
XS Wang, TR Mendoza, JB Broadway, et al. Symptom profiles in patients with chronic lymphocytic leukemia: validation and application of the MD Anderson Symptom Inventory [abstract]. Blood 114(22):1393, 2009.
Cleeland CS, Mendoza TR, Wang XS, et al. Assessing symptom distress in cancer: the M. D. Anderson Symptom Inventory. Cancer 89:1634-1646, 2000.
Clinical Application
Al-Sawaf O, Gentile B, Devine J, et al. Health-related quality of life with fixed-duration venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: Results from the randomized, phase 3 CLL14 trial. Am J Hematol 96(9):1112-1119, 2021.
Jain P, Keating M, Renner S, et al. Ruxolitinib for symptom control in patients with chronic lymphocytic leukaemia: a single-group, phase 2 trial. Lancet Haematol 4(2):e67-e74, 2017.
Every MDASI module contains:
all 13 MDASI core symptoms...
pain, fatigue, nausea, disturbed sleep, distress, shortness of breath, difficulty remembering, lack of appetite, drowsiness, dry mouth, sadness, vomiting, numbness/tingling
...and all 6 MDASI interference items
general activity, mood, work, relations with others, walking, enjoyment of life
Seeking patient report by using patient-reported outcomes tools, such as the MDASI-CLL, can help ensure that better treatment effectiveness is not achieved at the expense of patient quality of life.
Alessandra Ferrajoli, M.D.
Professor, MD Anderson Department of Leukemia